Tsubura E, Noma K, Ikemoto H, Mori T, Mikuni C, Oizumi K, Kashiwabara H, Itoh A, Uchino H, Sawada H
Department of Internal Medicine, National Sanatorium Toneyama Hospital.
Jpn J Antibiot. 1991 Mar;44(3):324-36.
A total of 43 patients, comprising 41 patients with oral candidiasis and 2 with esophageal candidiasis, were treated with miconazole (MCZ) gel to assess its efficacy and safety in treating upper digestive tract mycosis. The efficacy of the drug was evaluable in 33 of them, consisting of 32 patients with oral candidiasis and 1 with esophageal candidiasis. The clinical efficacy rate of the drug against oral candidiasis was 87.5% (28/32 patients), and the clinical response was good in the 1 evaluable patient with esophageal candidiasis. The safety of the drug was assessed in 40 patients. In 3 (7.5%) of them, nausea occurred as an adverse event, but was not particularly serious in any of them. No abnormal laboratory test values caused by the drug were observed. The results suggested that MCZ gel would be a very useful drug in treating oral and esophageal candidiasis.
共有43例患者接受了咪康唑(MCZ)凝胶治疗,其中包括41例口腔念珠菌病患者和2例食管念珠菌病患者,以评估其治疗上消化道真菌病的疗效和安全性。其中33例患者的药物疗效可评估,包括32例口腔念珠菌病患者和1例食管念珠菌病患者。该药物治疗口腔念珠菌病的临床有效率为87.5%(28/32例患者),1例可评估的食管念珠菌病患者临床反应良好。对40例患者评估了该药物的安全性。其中3例(7.5%)出现恶心这一不良事件,但均不特别严重。未观察到由该药物引起的实验室检查值异常。结果表明,MCZ凝胶在治疗口腔和食管念珠菌病方面将是一种非常有用的药物。